Gnaphaliin
Gnaphaliin is a flavonoid compound that exerts antioxidant, anti-inflammatory, and tracheal smooth muscle relaxant effects by inhibiting lipid peroxidation, scavenging free radicals, chelating trace elements, and reducing neutrophil infiltration. Gnaphaliin can be used in research on asthma, inflammation, and atherosclerosis.
For research use only. We do not sell to patients.
- CAS No.: 33803-42-8
- Formula: C17H14O6
- Molecular Weight:314.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LLC-MK2 | ED50 |
> 50 μM
|
Cytotoxicity against Rhesus monkey kidney LLC-MK2 cells assessed as effect on cell growth incubated for 24 hrs by [3H]-thymidine incorporation assay.
Cytotoxicity against Rhesus monkey kidney LLC-MK2 cells assessed as effect on cell growth incubated for 24 hrs by [3H]-thymidine incorporation assay.
|
11406849 |
| C6 | ED50 |
> 50 μM
|
Cytotoxicity against rat glial tumour C6 cells assessed as effect on cell growth incubated for 24 hrs by [3H]-thymidine incorporation assay.
Cytotoxicity against rat glial tumour C6 cells assessed as effect on cell growth incubated for 24 hrs by [3H]-thymidine incorporation assay.
|
11406849 |
In Vitro
Gnaphaliin (50-100 μM; 15 min) inhibits enzymatic lipid peroxidation in rat liver microsomes at 100 μM, but does not inhibit non-enzymatic lipid peroxidation[2].
Gnaphaliin (100 μM; 5 min) inhibits leukotriene B4 production in Calcimycin (A23187) (HY-N6687)-stimulated rat peritoneal leukocytes by 94% (20 pg/mL) at a concentration of 100 μM[2].
Gnaphaliin (3-15 μM; up to 30 min) inhibits Cu2+-induced LDL oxidation by delaying conjugated diene formation in a dose-dependent manner, with 3 μM extending the lag phase by approximately 30 min and 15 μM completely preventing diene conjugate formation[3].
Gnaphaliin (1-30 μM; up to 3 h) inhibits Cu2+-induced TBARS formation in human LDL with an IC50 of 8.0 μM[3].
Gnaphaliin (1-20 μM) inhibits Cu2+-induced increase in human LDL electrophoretic mobility in a dose-dependent manner[3].
Gnaphaliin (1-30 μM; 150 min) inhibits Cu2+-induced TBARS formation in diluted human plasma with an IC50 > 50 μM[3].
Gnaphaliin (6-50 μM; 24 h) is not cytotoxic and does not inhibit the growth of LLC-MK2 or C6 cells, with ED50 values > 50 μM[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Rat peritoneal polymorphonuclear leukocytes
-
Concentration:100 μM
-
Incubation Time:5 min
-
Result:Suppressed leukotriene B4 formation with levels of 20 pg/mL, corresponding to 94% inhibition.
In Vivo
Gnaphaliin (50 mg/kg; s.c.; single administration 3 h before serotonin injection) is the most active among the tested flavonoids in the serotonin-induced mouse paw edema model, producing less than 40% reduction in edema[2].
Gnaphaliin (15 mg/kg; i.p.; administered immediately before and 16 h after challenge) exerts only a mild anti-edema effect in the sheep red blood cell-induced delayed-type hypersensitivity model, and this effect persists after 48 h[2].
Gnaphaliin (500-62 μg/ear; topical administration; single co-administration with Phorbol 12-myristate 13-acetate (TPA) (HY-18739)) inhibits acute TPA-induced mouse ear edema with an ID50 of 0.210 mg/ear and an inhibition rate of 72% at 0.5 mg/ear[2].
Gnaphaliin (0.5 mg/ear; topical administration; twice daily for 4 days; on the last day, administered only in the morning) moderately reduces edema and decreases leukocyte infiltration in the chronic TPA-induced mouse ear inflammation model, but does not significantly reduce edema formation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (female, 25-30 g)[2]
-
Dosage:80 mg/kg
-
Administration:i.p.; single dose 30 min before phospholipase A2
-
Result:Reduced paw oedema after 30 min.
Reduced the inflammatory lesion by about 50% at 60 min.
The anti-inflammatory activity subsided after 90 min.
-
Animal Model:Swiss mice (female, 25-30 g)[2]
-
Dosage:50 mg/kg
-
Administration:s.c.; single dose 3 h before serotonin injection
-
Result:Slightly reduced oedema formation (< 40%).
Was the most active compound in this test.
-
Animal Model:Swiss mice (female, 25-30 g)[2]
-
Dosage:15 mg/kg
-
Administration:i.p.; administered immediately before and 16 h after challenge
-
Result:Had a slight anti-oedema effect after 48 h.
-
Animal Model:Swiss mice (female, 25-30 g)[2]
-
Dosage:0.5 mg/ear
-
Administration:topical; twice daily for 4 days; on the last day applied only in the morning
-
Result:Moderately reduced oedema.
Reduced neutrophil infiltration, measured as myeloperoxidase activity.
Chemical Information
-
CAS No. 33803-42-8
-
Molecular Weight 314.29
-
Formula C17H14O6
-
SMILES
O=C1C(OC)=C(C2=CC=CC=C2)OC3=C1C(O)=CC(O)=C3OC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gnaphaliin Related Classifications
HY-W747035 Related Classifications
Powered by Bioz